While systemic mTOR inhibition has been demonstrated to extend lifespan in multiple model organisms and improve many age‐related diseases, this treatment regimen also induces glucose intolerance due to elevated insulin resistance and hepatic gluconeogenesis (Johnson et al., 2013). Here, MTOR is linked to Insulin resistance.